Results 131 to 140 of about 5,574 (244)

Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy

AboutOpen
Background: The availability of high-efficacy disease-modifying therapy (DMT), including natalizumab, improved treatment efficacy in adults with highly-active relapsing-remitting multiple sclerosis (RRMS). Natalizumab patent protection has expired, and the natalizumab biosimilar (Tyruko®) has been recently reimbursed by AIFA.
Roberto Bergamaschi, Marco Capobianco, Roberto Ravasio   +2 more
openaire   +2 more sources

Innovation and market dynamics in the EPO market [PDF]

, 2006
We have estimated the demand of erythropoietin (EPO) on market data from the Nordic countries. Assuming that prices are set in a Nash-Bertrand game we determine the degree of competition in this Nordic market.
Sorisio, Enrico, Strøm, Steinar
core  

Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases

Rheumatology and Therapy
Introduction ABP 501 was an adalimumab (ADA) biosimilar approved for treating immune-mediated inflammatory diseases (IMIDs) including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS).
Ran Jin, Silvia Kruppert, Florian Scholz, Isabelle Bardoulat, Khalil Karzazi, Francois Morand, Greg Kricorian, David Collier, Jonathan Kay   +8 more
doaj   +1 more source

Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap (XM17), Comparability with Gonal-f, and Performance/Consistency [PDF]

, 2017

core   +1 more source

Strange Bedfellows: Native American Tribes, Big Pharma, and the Legitimacy of Their Alliance [PDF]

, 2019
Lost in the cacophony surrounding the debate about high drug prices is the fundamental principle that pharmaceutical innovation will not occur without the prospect of outsized returns enabled through market exclusivity.
Kennedy, Daniel C.
core   +1 more source

Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference Product

Ophthalmology and Therapy
Introduction ABP 938 is being developed as a biosimilar candidate to aflibercept reference product (RP), a biologic used for certain angiogenic eye disorders.
Neungseon Seo, Xiaoyan Guan, Tian Wang, Hyo S. Helen Chung, Mats Wikström, Rupa Padaki, Kevin Kalenian, Scott Kuhns, Kelli Matthies, Jill Crouse-Zeineddini, Helen Y. Wong, Michael Ng, Ian N. Foltz, Shawn Cao, Jennifer Liu   +14 more
doaj   +1 more source

The economic pressures for biosimilar drug use in cancer medicine [PDF]

, 2012
Paul Cornes
core   +1 more source

Comparative physicochemical and structural characterisation studies establish high biosimilarity between BGL-ASP and reference insulin aspart

Scientific Reports
Biosimilar insulin analogues are increasing market access for diabetic patients globally. Scientific establishment of biosimilarity is cornerstone of this key change in the medical landscape.
Nikhil S. Ghade, Damodar K. Thappa, Jeseena Lona, Archana R. Krishnan, Sanjay M. Sonar   +4 more
doaj   +1 more source

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

, 2014
223 ...
openaire   +1 more source

Innovation and market dynamics in the EPO market [PDF]

In this paper we study the demand and supply of erythropoietin in four Nordic countries, using an econometric model based on discrete choice and a random utility model.
Sorisio, Enrico, Strøm, Steinar
core